TNFRSF10B and cancer: In addition, since the structural difference between AF8c and lapatinib is in their solvent-exposed moieties (in respect to their design rationale as kinase inhibitors), we believe that this moiety could contribute to the observed selective upregulation of DR5 expression by AF8c, which could provide a tool for understanding the impact of selective DR5 upregulation in cancer cells.